article SARS-CoV-2 and immunology: antibody developments 15 February 2021 | By Victoria Rees (Drug Target Review) Discover the latest in SARS-CoV-2 antibody research as we cover three of the most recent developments in this article.
news Majority retain COVID-19 antibodies for six months after infection 3 February 2021 | By Victoria Rees (Drug Target Review) A study has shown that 88 percent of people infected by COVID-19 were able to produce SARS-CoV-2 antibodies after six months.
news Thapsigargin could be used as antiviral to treat COVID-19, study shows 3 February 2021 | By Victoria Rees (Drug Target Review) Researchers have discovered that thapsigargin has novel antiviral properties and is effective against COVID-19 in pre-clinical studies.
news Novel protein could neutralise SARS-CoV-2 infection in kidneys 2 February 2021 | By Victoria Rees (Drug Target Review) A new protein can trick SARS-CoV-2 and bind to the Spike protein rather than cell membranes in a kidney organoid.
news T cells target broad range of SARS-CoV-2 epitopes, study shows 29 January 2021 | By Victoria Rees (Drug Target Review) A study has found that T cells combat SARS-CoV-2 by targeting many sites on the coronavirus, not just the Spike protein.
news New database to track neurological symptoms of COVID-19 28 January 2021 | By Hannah Balfour (Drug Target Review) NeuroCOVID will be a resource of clinical information and biospecimens from people who experience neurological problems associated with SARS-CoV-2 infection.
news Melatonin could act as barrier against SARS-CoV-2 infection 28 January 2021 | By Victoria Rees (Drug Target Review) Researchers have suggested using melatonin in a nasal spray to create a protective barrier against SARS-CoV-2 in pre-symptomatic patients.
news Biomarker in blood could determine severity of COVID-19 27 January 2021 | By Victoria Rees (Drug Target Review) A study has shown that patients with severe COVID-19 have significantly elevated levels of M-MDSCs in their blood compared with healthy individuals.
news Rhesus macaques with SARS-CoV-2 develop promising immune response 25 January 2021 | By Victoria Rees (Drug Target Review) A study has shown that the immune response of rhesus macaques with SARS-CoV-2 could be reproduced with a vaccine.
news SARS-CoV-2 triggers antibodies from previous coronavirus infections 22 January 2021 | By Victoria Rees (Drug Target Review) A new study has shown that previous coronavirus infection may contribute to the immune response of patients infected with SARS-CoV-2.
news Artificial intelligence analyses how viruses evade the immune system 15 January 2021 | By Hannah Balfour (Drug Target Review) The natural language processing model trained using viral protein sequence data was able to predict promising targets for vaccines against HIV, influenza and coronaviruses.
news SARS-CoV-2 infects CNS and damages brain tissue, study shows 13 January 2021 | By Victoria Rees (Drug Target Review) Researchers have shown in cells and models that the central nervous system and neurons can become a target of SARS-CoV-2 infection.
news Macaques and baboons show success as models to study SARS-CoV-2 6 January 2021 | By Victoria Rees (Drug Target Review) Researchers have shown rhesus macaques and baboons develop strong signs of acute viral infection from SARS-CoV-2, making them ideal models.
news Blood vessel damage likely causes neurological symptoms of COVID-19, finds study 4 January 2021 | By Hannah Balfour (Drug Target Review) A new study suggests that inflammation and blood vessel damage may be the primary causes of neurological symptoms in COVID-19 patients, instead of the virus infecting the brain.
article COVID-19 drug development based on boosting immunity 31 December 2020 | By Baidyanath Dash (G3 Systems) Baidyanath Dash explains the two requirements for COVID-19 drug development: killing the virus and boosting immunity.
